FDA Approves Drug for Adult and Pediatric Patients Aged 6 and Older with Allergic Fungal Rhinosinusitis

Why It Matters

Dupixent provides the first non‑surgical, disease‑modifying option for AFRS, potentially lowering invasive procedures and long‑term steroid exposure. This shifts the therapeutic landscape for a condition that can cause severe bone erosion and vision loss.

Key Takeaways

• FDA approves Dupixent for AFRS in patients 6+.
• First therapy targeting allergic fungal sinusitis.
• Study shows reduced surgery and steroid use.
• Improves CT scores, nasal polyps, smell.
• Safety aligns with existing Dupixent profile.

Pulse Analysis

Allergic fungal rhinosinusitis (AFRS) remains a niche yet severe form of chronic sinus disease, affecting up to 8 % of patients with nasal polyps. The condition typically emerges in adolescence, producing thick, peanut‑butter‑like mucus that can erode bone in up to 90 % of cases and threaten vision or brain structures. Because surgical intervention carries significant risk and recurrence is common, clinicians have long sought a medical therapy that can halt disease progression without repeated operations.

Dupilumab, the monoclonal antibody sold as Dupixent, blocks interleukin‑4 and interleukin‑13 signaling, key drivers of type‑2 inflammation. In a 52‑week, placebo‑controlled trial involving patients aged six and older, dupilumab produced statistically significant reductions in Lund‑Mackay CT scores, nasal polyp size, congestion, and olfactory loss. Equally important, the drug cut the need for systemic corticosteroids and sinus surgery, while also diminishing bone erosion—a complication unique to AFRS. Safety outcomes mirrored the well‑characterized profile seen in chronic rhinosinusitis with nasal polyps.

The FDA’s approval marks the first disease‑specific treatment for AFRS, opening a new revenue stream for Sanofi‑Regeneron and setting a precedent for biologic therapy in rare sinus disorders. Patients now have an option that can be administered in an outpatient setting, potentially reducing healthcare costs associated with repeated surgeries and long‑term steroid use. As real‑world data accumulate, payers will likely reassess coverage policies, and specialists may incorporate dupilumab earlier in the treatment algorithm, reshaping standards of care for this underserved population.